Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model
Objective. Increase in the low-density lipoprotein (LDL) level in diabetes mellitus and atherosclerosis is related to lipoprotein associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that produces lysophosphatidylcholine (LysoPC) and oxidized nonesterified fatty acids (oxNEFA). LysoPC regulat...
Main Authors: | Wihastuti Titin Andri, Heriansyah Teuku, Hanifa Hanifa, Andarini Sri, Sholichah Zuhrotus, Sulfia Yuni Hendrati, Adam Aditya Angela, Refialdinata Jeki, Lutfiana Nurul Cholifah |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2018-04-01
|
Series: | Endocrine Regulations |
Subjects: | |
Online Access: | https://doi.org/10.2478/enr-2018-0008 |
Similar Items
-
Elaborate evaluation of serum and tissue oxidized LDL level with darapladib therapy: A feasible diagnostic marker for early atherogenesis
by: Teuku Heriansyah, et al.
Published: (2017-02-01) -
Lp-PLA2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus
by: Wihastuti TA, et al.
Published: (2019-11-01) -
Développement, synthèse et marquage au fluor-18 de ligands de la Lp-PLA2 pour la détection précoce de plaques d’athérome par imagerie TEP.
by: Guibbal, Florian
Published: (2017) -
The inhibitory effects of polysaccharide peptides (PsP) of Ganoderma lucidum against atherosclerosis in rats with dyslipidemia
by: Titin Andri Wihastuti, et al.
Published: (2017-04-01) -
Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2
by: Robert S. Rosenson, et al.
Published: (2012-09-01)